NEW YORK, June 27 - Short interfering RNA therapeutics firm Alnylam will likely have products in the clinic within two to three years, CEO John Maraganore said in an interview at the BIO 2003 meeting in Washington, D.C. this week.
Registering provides access to this and other free content.
Already have an account?Login Now.
The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.
Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.
In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.
China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.